Skip to main content

Table 2 Treatment characteristics and laboratory variables of the patients in the first 6 months of follow-up

From: Clinical outcomes of hemodialysis patients in a public-private partnership care framework in Italy: a retrospective cohort study

 

Prevalent patients

Incident patients

All patients

n = 197

n = 204

n = 401

Most frequently applied treatment modalitya

 hf-HD

82 (41.6)

178 (87.3)

260 (64.8)

 post- HDF

92 (46.7)

22 (10.8)

114 (28.4)

 mixed- HDF

23 (11.7)

4 (2.0)

27 (6.7)

Most frequently applied vascular access typea

 AV Fistula

145 (73.6)

115 (56.4)

260 (64.8)

 Permanent central vascular catheter

30 (15.2)

57 (27.9)

87 (21.7)

 Temporary central vascular catheter

1 (0.5)

31 (15.2)

32 (8.0)

 Graft

17 (8.6)

1 (0.5)

18 (4.5)

 Not known

4 (2.0)

0 (0)

4 (1.0)

 Effective treatment time, min

232.4 (11.7)

237.5 (10.9)

235.0 (11.6)

Blood flow rate, ml/min

354.8 (45.7)

292.7 (52.9)

323.2 (58.4)

Convective volume, L/session

 On post-HDF

27.8 (4.4)

30.5 (11.5)

28.3 (6.4)

 On mixed- HDF

42.7 (4.1)

40.2 (3.0)

42.3 (4.0)

Substitution volume, L/session

 On post- HDF

25.7 (4.4)

28.7 (11.8)

26.3 (6.5)

 On mixed- HDF

40.3 (4.1)

37.4 (2.9)

39.9 (4.0)

 % of total substitution volume infused in post-dilution in mixed-HDF

54 (8)

64 (2)

55 (8)

 OCM KtV

1.65 (0.25)

1.54 (0.35)

1.59 (0.31)

 Dry body weight, kg

68.1 (13.7)

71.3 (14.7)

69.7 (14.3)

 Average overhydrationb

12.2 (7.1)

12.2 (7.1)

12.2 (7.1)

 Relative overhydration, %c

10.4 (6.8)

10.5 (6.8)

10.5 (6.8)

Laboratory variables

 Hemoglobin, g/dl

11.2 (0.9)

10.4 (1.0)

10.8 (1.0)

 Ferritin, μg/l

402.0 (253.8)

185.1 (199.1)

295.0 (252.7)

 Transferrin saturation, %

27.9 (15.5)

21.6 (10.6)

24.8 (13.7)

 Albumin, g/dl

3.6 (0.4)

3.5 (0.5)

3.5 (0.4)

 Total calcium, mg/dl

9.0 (0.5)

8.9 (0.5)

8.9 (0.5)

 Phosphate, mg/dl

4.0 (1.1)

4.3 (1.1)

4.2 (1.1)

 Intact Parathormon, pg/ml

183.0 (147.1)

206.8 (158.7)

194.4 (153.1)

 C-reactive protein, mg/ld

0.8 [0.3; 4.9]

4.0 [1.4; 14.3]

2.1 [0.5; 9.0]

 Total cholesterol, mg/dl

161.6 (37.6)

170.6 (42.9)

165.8 (40.4)

 HDL cholesterol, mg/dl

43.1 (17.4)

45.1 (14.9)

44.1 (16.3)

 LDL cholesterol, mg/dl

86.2 (28.4)

97.2 (34.7)

91.4 (31.9)

 Triglycerides, mg/dl

152.7 (70.9)

149.4 (73.4)

151.1 (72.0)

  1. The data were expressed as mean (standard deviation) or number (%), as appropriate except where indicated
  2. aThe most frequently applied treatment characteristic per patient during the 6-month follow-up period is considered for the calculations
  3. bAverage overhydration was calculated as (predialysis body weight – normohydration body weight) [kg] / extracellular fluid [L] × 100
  4. cRelative overhydration was calculated as (predialysis body weight – postdialysis body weight) [kg] / extracellular fluid [L]
  5. dThe C-reactive protein values were not normally distributed. Therefore, these data are expressed as median (interquartile ranges)
  6. For all laboratory and treatment parameters, except the number of treatment sessions, multiple measurements during the 6-month follow-up period were averaged for each patient, and the descriptive statistics presented in this table was calculated based on these patient means
  7. AV arteriovenous, HDL high-density lipoprotein, hf-HD high-flux hemodialysis, LDL low-density lipoprotein, mixed-HDF online mixed-dilution hemodiafiltration, OCM online clearance monitor, post-HDF online post-dilution hemodiafiltration
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us